NLRP3 and Alzheimer disease: First, we found that reduced neuroinflammation with NF-κB/NLRP3-targeting Nanoligomers was associated with reductions in total and phosphorylated tau species representative of both early and later aging/AD pathology in rTg4510 mice [39, 40].